This 75-minute webinar will present the data for Biogen’s investigational drug aducanumab, which if approved, would be the first disease-modifying treatment for Alzheimer’s disease.
Featured news and events
Alzheimer’s Disease International (ADI) launches the world’s most comprehensive report on dementia-related design and the built environment.
The AD/PD™ conference brings together medical and scientific professionals, interested in Alzheimer's and Parkinson's disease, from around the world.
We have a new website, with updated design and content. The site works better on mobile devices and brings together our resources, member information and programmes so they are easy to find.
Fiona Walsh writes about designing around the different challenges a person with dementia may experience – and how these design decisions can have a significant impact on a person’s dignity and independence
‘Dementia Innovation Readiness Index 2020: 30 Global Cities’ calls strongly for cities to fulfil their commitments under the WHO’s Global action plan on dementia to engage fully with their national dementia plans.
On World Alzheimer’s Day, Hilary Doxford, a dementia advocate and member of the 3 Nations Dementia Working Group and World Dementia Council, shares her views and experiences – as well as those of her friends and fellow advocates – of living with dementia in the UK during the Covid-19 pandemic.
Two new reports highlight the challenges faced by health systems in the United States and five European countries to ensure preparedness for potentially imminent Alzheimer’s biomarker and treatment breakthroughs.
The Lancet launches new guidance which reveals that an extended set of 12 modifiable risk factors might prevent or delay up to 40 per cent of dementia cases globally.